BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 29515105)

  • 21. CD44 standard isoform is involved in maintenance of cancer stem cells of a hepatocellular carcinoma cell line.
    Asai R; Tsuchiya H; Amisaki M; Makimoto K; Takenaga A; Sakabe T; Hoi S; Koyama S; Shiota G
    Cancer Med; 2019 Feb; 8(2):773-782. PubMed ID: 30636370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CPEB1 mediates hepatocellular carcinoma cancer stemness and chemoresistance.
    Xu M; Fang S; Song J; Chen M; Zhang Q; Weng Q; Fan X; Chen W; Wu X; Wu F; Tu J; Zhao Z; Ji J
    Cell Death Dis; 2018 Sep; 9(10):957. PubMed ID: 30237545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of VEGFR-2 inhibitors exerting significant anticancer activity against CD44+ and CD133+ cancer stem cells (CSCs): Reversal of TGF-β induced epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma.
    Modi SJ; Kulkarni VM
    Eur J Med Chem; 2020 Dec; 207():112851. PubMed ID: 33002846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. NEAT1 is Required for the Expression of the Liver Cancer Stem Cell Marker CD44.
    Koyama S; Tsuchiya H; Amisaki M; Sakaguchi H; Honjo S; Fujiwara Y; Shiota G
    Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32168951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chitosan promotes cancer progression and stem cell properties in association with Wnt signaling in colon and hepatocellular carcinoma cells.
    Chang PH; Sekine K; Chao HM; Hsu SH; Chern E
    Sci Rep; 2017 Apr; 8():45751. PubMed ID: 28367998
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner.
    Ishigami I; Shuwari N; Kaminade T; Mizuguchi H; Sakurai F
    Anticancer Res; 2021 May; 41(5):2431-2440. PubMed ID: 33952468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
    Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
    Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
    Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
    Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDAC11 Regulates Glycolysis through the LKB1/AMPK Signaling Pathway to Maintain Hepatocellular Carcinoma Stemness.
    Bi L; Ren Y; Feng M; Meng P; Wang Q; Chen W; Jiao Q; Wang Y; Du L; Zhou F; Jiang Y; Chen F; Wang C; Tang B; Wang Y
    Cancer Res; 2021 Apr; 81(8):2015-2028. PubMed ID: 33602787
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BMP9-ID1 signaling promotes EpCAM-positive cancer stem cell properties in hepatocellular carcinoma.
    Chen H; Nio K; Yamashita T; Okada H; Li R; Suda T; Li Y; Doan PTB; Seki A; Nakagawa H; Toyama T; Terashima T; Iida N; Shimakami T; Takatori H; Kawaguchi K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
    Mol Oncol; 2021 Aug; 15(8):2203-2218. PubMed ID: 33834612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relation of type II transforming growth factor-beta receptor to hepatic fibrosis and hepatocellular carcinoma.
    Ueno T; Hashimoto O; Kimura R; Torimura T; Kawaguchi T; Nakamura T; Sakata R; Koga H; Sata M
    Int J Oncol; 2001 Jan; 18(1):49-55. PubMed ID: 11115538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic relevance of miR-137 in patients with hepatocellular carcinoma.
    Sakabe T; Azumi J; Umekita Y; Toriguchi K; Hatano E; Hirooka Y; Shiota G
    Liver Int; 2017 Feb; 37(2):271-279. PubMed ID: 27473646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
    Chu TH; Chan HH; Kuo HM; Liu LF; Hu TH; Sun CK; Kung ML; Lin SW; Wang EM; Ma YL; Cheng KH; Lai KH; Wen ZH; Hsu PI; Tai MH
    Oncotarget; 2014 Mar; 5(6):1475-90. PubMed ID: 24721996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A positive feedback loop between Periostin and TGFβ1 induces and maintains the stemness of hepatocellular carcinoma cells via AP-2α activation.
    Chen G; Wang Y; Zhao X; Xie XZ; Zhao JG; Deng T; Chen ZY; Chen HB; Tong YF; Yang Z; Ding XW; Guo PY; Yu HT; Wu LJ; Zhang SN; Zhu QD; Li JJ; Shan YF; Yu FX; Yu ZP; Xia JL
    J Exp Clin Cancer Res; 2021 Jun; 40(1):218. PubMed ID: 34193219
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipopolysaccharide supports maintaining the stemness of CD133(+) hepatoma cells through activation of the NF-κB/HIF-1α pathway.
    Lai FB; Liu WT; Jing YY; Yu GF; Han ZP; Yang X; Zeng JX; Zhang HJ; Shi RY; Li XY; Pan XR; Li R; Zhao QD; Wu MC; Zhang P; Liu JF; Wei LX
    Cancer Lett; 2016 Aug; 378(2):131-41. PubMed ID: 27208741
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
    Liu X; Yu M; Chen Y; Zhang J
    Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The osteopontin-CD44 axis in hepatic cancer stem cells regulates IFN signaling and HCV replication.
    Shirasaki T; Honda M; Yamashita T; Nio K; Shimakami T; Shimizu R; Nakasyo S; Murai K; Shirasaki N; Okada H; Sakai Y; Sato T; Suzuki T; Yoshioka K; Kaneko S
    Sci Rep; 2018 Sep; 8(1):13143. PubMed ID: 30177680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Emodin is a Potential Drug Targeting CD44-positive Hepatocellular Cancer.
    Gao Y; Li Y; Zhu Y; Luo Q; Lu Y; Wen K; Du B; Xi X; Li G
    Curr Cancer Drug Targets; 2024; 24(5):510-518. PubMed ID: 38099524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of TGF-β1 and C-Kit Mutations in the Development of Hepatocellular Carcinoma in Hepatitis C Virus-Infected Patients: in vitro Study.
    El-Houseini ME; Ismail A; Abdelaal AA; El-Habashy AH; Abdallah ZF; Mohamed MZ; El-Hadidi M; Cho WCS; Ahmed H; Al-Shafie TA
    Biochemistry (Mosc); 2019 Aug; 84(8):941-953. PubMed ID: 31522676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.